GREM1

Across TCGA pan-cancer cohorts, GREM1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GREM1 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GREM1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GREM1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where GREM1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.214	0.785	.006	10	view →
HNSC	DFS	Tertile	All	0.947	0.331	.014	10	view →
LSCC	DFS	Tertile	II,III,IV	0.591	0.896	.027	3	view →
CCRCC	OS	Median	All	0.907	0.710	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GREM1–PDAC (DFS)

Open the PDAC breakdown →